# BRE09-146: postoperative cisplatin with or without rucaparib

Source: https://onco.cc/trials/nct01074970/  
OnCo record `nct01074970` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This completed study tested extra treatment for breast cancer remaining after chemotherapy and surgery. Adding the tested low-dose rucaparib regimen did not significantly improve two-year disease-free survival.

## Summary

Registry completed, last updated 2024-09-19. Postoperative TNBC or BRCA-mutated breast cancer with residual tumour greater than 2 cm or persistent nodal involvement after neoadjuvant therapy. The registry records 135 enrolled; the paper reports 128 randomized. Low rucaparib exposure and the historical regimen limit extrapolation to other PARP strategies.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-10-10
- Registry id: NCT01074970
- Phase: 2
- Setting: Postoperative TNBC or BRCA-mutated breast cancer with residual tumour greater than 2 cm or persistent nodal involvement after neoadjuvant therapy
- Sponsor: Hoosier Cancer Research Network
- Enrolled: 135

## Sources

- ClinicalTrials.gov NCT01074970: https://clinicaltrials.gov/study/NCT01074970

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Rucaparib](https://onco.cc/drugs/rucaparib/)
- key papers: [BRE09-146: cisplatin with or without rucaparib after preoperative breast chemotherapy](https://onco.cc/key-papers/paper-kalra-bre09-146-rucaparib-npj-2021/)

---
JSON: https://onco.cc/api/v1/entities/nct01074970.json